The DOI matches its Crossref record; 64 of the 65 references it cites were found in a registry or an index; 38 of the 43 sources its claims cite were checked for support.
Modest changes in Spi1 dosage reveal the potential for altered microglial function as seen in Alzheimer’s disease
Open accessPublished version of a preprint
Abstract
Genetic association studies have identified multiple variants at the SPI1 locus that modify risk and age of onset for Alzheimer’s Disease (AD). Reports linking risk variants to gene expression suggest that variants denoting higher SPI1 expression are likely to have an earlier AD onset, and several other AD risk genes contain PU.1 binding sites in the promoter region. Overall, this suggests the level of SPI1 may alter microglial phenotype potentially impacting AD. This study determined how the microglial transcriptome was altered following modest changes to Spi1 expression in primary mouse microglia. RNA-sequencing was performed on microglia with reduced or increased Spi1/PU.1 expression to provide an unbiased approach to determine transcriptomic changes affected by Spi1. Reduction in microglial Spi1 resulted in the dysregulation of transcripts encoding proteins involved in DNA replication pathways while an increased Spi1 results in an upregulation of genes associated with immune response pathways. In addition, 194 Spi1 dose-sensitive genes were identified, affecting innate immune and interferon response pathways.
Overview
CoChat Summary
## TL;DR
Modest bidirectional changes in Spi1/PU.1 expression in primary mouse microglia caused large transcriptomic shifts: reduced Spi1 mainly affected cell cycle/DNA repair genes, while increased Spi1 enriched immune, interferon, and antigen-presentation pathways. The authors identify 194 Spi1 dose-sensitive genes and report that a subset of over-expression–linked genes was enriched for AD genetic risk.
## Key findings
- Spi1 knock-down in sorted microglia changed 1615 genes up and 1462 genes down at adjusted p < 0.05; 230 down-regulated genes exceeded the -2 log2 fold-change cut-off.
- Spi1 over-expression changed 284 genes up and 62 genes down at p < 0.05; 71 up-regulated and 4 down-regulated genes exceeded a log2 fold-change of 2.
- Comparing knock-down and over-expression identified 194 Spi1 dose-sensitive genes: 162 decreased with knock-down and increased with over-expression, and 32 showed the opposite pattern; these were enriched for immune response, especially interferon and viral defence pathways.
- GO analysis found lower Spi1 was most strongly associated with cell cycle and DNA repair pathways, while higher Spi1 was associated with antigen presentation, immune system processes, and response to interferon.
- In a comparison to IGAP AD GWAS data, a 21-gene set from the over-expression dataset (genes with Benjamini–Hochberg adjusted p ≤ 1 × 10−6 for differential expression) was enriched for AD genetic risk (adjusted p = 0.035).
## Methods
- Primary mixed glia were prepared from 8-week-old C57BL/6J mouse brains; the cultures were repeated 10 times (n = 10), with 4 used for RNA-seq and 6 for validation experiments.
- Microglia were infected on day 10 with Spi1 shRNA, control shRNA, Spi1 pSIEW over-expression, or pSIEW control lentivirus; microglia were then sorted by CD11b/CD45 and GFP before RNA-seq.
- RNA-seq used TruSeq stranded total RNA with Ribo-Zero GOLD, HiSeq 2500 sequencing at 30–40 million pairs, alignment with STAR, differential expression with DESeq2, GO analysis with DAVID, clustering in R, PU.1 binding-site overlap with a published ChIP-seq dataset, and AD-risk enrichment with MAGMA using IGAP data.
## Limitations
- The paper states that the cultures were supplemented with TGF-β, which “partially compensates” for missing environmental cues, but does not fully replicate the in vivo context; it also states there were no suitable transgenic mice available to study Spi1 dose in situ.
- The authors note that pathway inference from RNA-seq does not prove phenotype and that further work would be required to confirm experimentally whether higher Spi1 truly makes microglia more interferon-responsive.
- Evident from the text: the study is in primary mouse microglia/mixed glia, so direct applicability to human AD biology is uncertain, and the manuscript itself notes possible species differences between human and mouse microglia.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
28 Valid · 2 Not valid · 5 Not checked · 55 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“SPI1 encodes PU.1, a central transcription factor in microglial development and activation, and has a genome-wide significant genic association with AD in the IGAP GWAS (rs3740688 Odds Ratio 0.92 Meta p = 5.4 × 10−13), comprising 35,274 Alzheimer’s disease cases and 59,163 controls4.”
§ Modest changes in Spi1 dosage reveal the potential for altered microglial function as seen in Alzheimer’s disease > Introduction
What the sources say
- Partly supportedcites [4] Kunkle, B. W. et al. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nat Genet. 51, 414–430 (2019). sourceExperimental — accuracy not yet measured
The Results (Meta-analysis of Alzheimer’s disease GWAS; page unavailable) give the stated sample size of 35,274 cases and 59,163 controls. Candidate gene prioritization (page unavailable) identifies SPI1 as a gene implicated at a genome-wide AD risk locus. The passages in our copy do not verify rs3740688, its odds ratio of 0.92, or the stated P value of 5.4 × 10−13. (LLM, conf=0.86)
plainstates an associationn = 35,274- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, a 56-protein interaction network consisting of strongly enriched rare coding variants (p = 1.08 × 10–7, and common variants with Late-Onset AD gene-wide significance (p = 2.98 × 10–7) identified SPI1 as a central hub gene5.”
§ Modest changes in Spi1 dosage reveal the potential for altered microglial function as seen in Alzheimer’s disease > Introduction
What the sources say
- Partly supportedcites [5] Sims, R. et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer’s disease. Nat. Genet. 49(9), 1373–1384 (2017). sourceExperimental — accuracy not yet measured
The Online Methods (Protein interaction Analysis; Gene-set enrichment analysis of the protein network, page unavailable) describe a 56-gene interaction network and report P=1.08×10⁻⁷ for rare-variant enrichment. But P=2.98×10⁻⁷ is from a conservative rare-variant analysis, not the common-variant analysis. The paper says SPI1 is in the network and is a central transcription factor in microglial activation; it does not identify SPI1 as the network’s central hub gene. (LLM, conf=0.87)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Reports linking risk variants to gene expression suggest that variants denoting higher SPI1 expression are likely to have an earlier AD onset”
- Also stated in: § Introduction · hedged
“The SNP variant rs1057233a is thought to result in a higher level of Spi1 expression and earlier age of AD onset7.”
§ Modest changes in Spi1 dosage reveal the potential for altered microglial function as seen in Alzheimer’s disease > Abstract
What the sources say
- Supportedcites [7] Huang, K. et al. A common haplotype lowers SPI1 (PU.1) expression in myeloid cells and delays age at onset for Alzheimer’s disease. Nat. Neurosci. 20, 1052–1061 (2017). source
The Results section (Conditional and SMR analysis of the SPI1/CELF1 locus; page unavailable) links variants affecting SPI1 expression in myeloid cells to AD survival. The Discussion (page unavailable) says lower SPI1 expression is protective, supporting the citing sentence’s hedged inference that variants associated with higher expression are likely linked to earlier onset. (LLM, conf=0.86)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Introduction · hedged
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Genetic association studies have identified multiple variants at the SPI1 locus that modify risk and age of onset for Alzheimer’s Disease (AD).”
- Also stated in: § Introduction · hedged
“Several single-nucleotide polymorphisms (SNPs) associated with an increased risk of AD are thought to lie within the Spi1 gene locus3,6,7.”
§ Modest changes in Spi1 dosage reveal the potential for altered microglial function as seen in Alzheimer’s disease > Abstract
What the sources say
- Partly supportedcites [3] Escott-Price, V. et al. Gene-wide analysis detects two new susceptibility genes for Alzheimer’s disease. PLoS ONE 9(6), 94661 (2014). sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports a gene-based genome-wide significant association between the chromosome 11 SPI1–MTCH2 cluster and Alzheimer’s disease, supporting the risk-association portion of the claim. The paper does not establish that multiple distinct variants at SPI1 modify risk, and the passages on age of onset do not report an association with age of onset. (LLM, conf=0.86)
- Partly supportedcites [6] Gjoneska, E. et al. Conserved epigenomic signals in mice and humans reveal immune basis of Alzheimer’s disease. Nature 518, 365–369 (2015). sourceExperimental — accuracy not yet measured
The passage discussing the CELF1/SPI1 locus (page not provided) identifies multiple AD-associated variants near SPI1, supporting the genetic-association and risk portion of the claim. It does not report that these variants modify age of onset, and its enhancer assay does not establish that they causally modify AD risk. (LLM, conf=0.88)
- Supportedcites [7] Huang, K. et al. A common haplotype lowers SPI1 (PU.1) expression in myeloid cells and delays age at onset for Alzheimer’s disease. Nat. Neurosci. 20, 1052–1061 (2017). source
The Results section on conditional and SMR analysis (page unavailable) states that rs1057233 and its tagging SNPs are associated with AD risk and survival, the paper’s measure of age at onset. It also cautions that the variants are in high linkage disequilibrium and does not identify which one is functional. (LLM, conf=0.90)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Introduction · hedged
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition to SPI1 binding sites being located near other AD risk genes or regulatory elements5,7,8, SPI1 risk alleles associated with a higher gene expression have been shown to lower the age of onset in AD7.”
§ Modest changes in Spi1 dosage reveal the potential for altered microglial function as seen in Alzheimer’s disease > Discussion
What the sources say
- Supportedcites [7] Huang, K. et al. A common haplotype lowers SPI1 (PU.1) expression in myeloid cells and delays age at onset for Alzheimer’s disease. Nat. Neurosci. 20, 1052–1061 (2017). source
The Results (Genome-wide survival analysis; page not provided) state that AD risk-increasing alleles were associated with earlier age at onset. The Discussion (page not provided) reports that the protective rs1057233G allele was associated with both lower SPI1 expression and later age at onset, supporting the claimed inverse direction. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
59 more claims · 13 with their cited sources checked
Create a free account to see all 90 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 14
- It may state two separate claims as one. 15
- Borderline: one of the tests for a substantial claim is unclear. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This creates a central tension for Alzheimer’s therapeutics: lowering PU.1 may reduce risk-associated or inflammatory programs, but too much suppression could compromise microglial survival, plaque engagement, phagocytosis, or other protective functions.”
From Lymphoid-like Suppressive Microglia in Alzheimer’s Disease: A New Neuroimmune Regulatory Axis? (2026) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, studies of Spi1 dosage in mice suggest that modest changes can reshape the microglial transcriptome, but the biological consequences depend on timing, magnitude, and disease context [33].”
From Lymphoid-like Suppressive Microglia in Alzheimer’s Disease: A New Neuroimmune Regulatory Axis? (2026) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Because PU.1 is required for microglial identity and viability, excessive reduction may impair essential functions.”
From Lymphoid-like Suppressive Microglia in Alzheimer’s Disease: A New Neuroimmune Regulatory Axis? (2026) · cites this paper as [33]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“As a transcription factor, PU.1 may orchestrate the expression of multiple target genes involved in phagocytosis and immune responses39–41.”
From Deletion of SPI1 in microglia exacerbates amyloid pathology by impairing microglial response in Alzheimer’s disease models (2026) · cites this paper as [41]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Human genetic studies suggest that reduced SPI1 expression may be protective, whereas experimental data indicate that excessive PU.1 suppression can impair essential microglial functions.”
From Lymphoid-like Suppressive Microglia in Alzheimer’s Disease: A New Neuroimmune Regulatory Axis? (2026) · cites this paper as [33]
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Trimmomatic: a flexible trimmer for Illumina sequence data
Bolger, A. M., Lohse, M., & Usadel, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu170 · Cited by 65,548 · cited 2×
“The FASTQ files were processed with Trimmomatic [47] to remove paired-end reads and quality was confirmed in FastQC using default parameters [48].”
MethodSTAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219 · cited 1×
“Following this sequence reads were mapped to the mm10 genome (GRCm38) using the STAR pipeline [49] and featureCounts was used to assign counts to transcripts [50] with the GRCm38.”
MethodWickham, H., Averick, M., Bryan, J., Chang, W., McGowan, L., François, R., Grolemund, G., Hayes, A., Henry, L., Hester, J., et al. (2019) · Journal of Open Source Software · doi:10.21105/joss.01686 · Cited by 22,138
Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y. C., Laslo, P., Cheng, J. X., Murre, C., Singh, H., & Glass, C. K. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.05.004 · Cited by 13,382
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336 · cited 1×
“Enrichment of association signal in IGAP GWAS data As Spi1 has been implicated in the regulation of other AD risk gene expression, both RNA-Seq datasets were tested for enrichment of association with AD risk in the International Genomics of Alzheimer’s Project (IGAP) GWAS dataset [56].”
BackgroundMAGMA: Generalized Gene-Set Analysis of GWAS Data
de Leeuw, C. A., Mooij, J. M., Heskes, T., & Posthuma, D. (2015) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1004219 · Cited by 3,653
Alzheimer Disease Genetics Consortium (ADGC), Kunkle, B. W., The European Alzheimer’s Disease Initiative (EADI), Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium (CHARGE), Genetic and Environmental Risk in AD/Defining Genetic, P. A. E. R. F. A. D. C. (., Grenier-Boley, B., Sims, R., Bis, J. C., Damotte, V., Naj, A. C., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0358-2 · Cited by 2,946 · cited 1×
“4 ×10), comprising 35,274 Alzheimer's disease cases and 59,163 controls [4].”
BackgroundIdentification of a unique TGF-β–dependent molecular and functional signature in microglia
Butovsky, O., Jedrychowski, M. P., Moore, C. S., Cialic, R., Lanser, A. J., Gabriely, G., Koeglsperger, T., Dake, B., Wu, P. M., Doykan, C. E., et al. (2014) · Nature Neuroscience · doi:10.1038/nn.3599 · Cited by 2,543 · cited 1×
“TGF-β supplementation was used to promote a more homeostatic phenotype in vitro [43,44].”
Method
Research works printed but not linked: 1
- Prince, M. et al. Dementia UK: Second Edition - Overview 61 (Alzheimer's Society, 2014).
Cited by
Alzheimer’s Disease: An Updated Overview of Its Genetics
Andrade-Guerrero, J., Santiago-Balmaseda, A., Jeronimo-Aguilar, P., Vargas-Rodríguez, I., Cadena-Suárez, A. R., Sánchez-Garibay, C., Pozo-Molina, G., Méndez-Catalá, C. F., Cardenas-Aguayo, M.-D.-C., Diaz-Cintra, S., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043754 · Cited by 336
“1 (SPI1), involved in the expression of immune-related genes in myeloid cells, could contribute to AD by regulating key pathways associated with the immune response and altering the epigenetic landscape [47,48].”
BackgroundThe neuroimmune axis of Alzheimer’s disease
Jorfi, M., Maaser-Hecker, A., & Tanzi, R. E. (2023) · Genome Medicine · doi:10.1186/s13073-023-01155-w · Cited by 292
Ocañas, S. R., Pham, K. D., Cox, J. E. J., Keck, A. W., Ko, S., Ampadu, F. A., Porter, H. L., Ansere, V. A., Kulpa, A., Kellogg, C. M., et al. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02870-2 · Cited by 86
“Since SPI1 is a critical microglial transcription factor, even small changes in activity may lead to different susceptibilities to AD [52].”
BackgroundInfluentialZhang, G., Lü, J., Zheng, J., Mei, S., Li, H., Zhang, X., Ping, A., Gao, S., Fang, Y., & Yu, J. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.375343 · Cited by 66
“Previous studies have suggested that Spi1 modulates the microglial transcriptome and promotes phagocytosis (Jones et al., 2021; Pimenova et al., 2021).”
BackgroundPodleśny-Drabiniok, A., Novikova, G., Liu, Y., Dunst, J., Temizer, R., Giannarelli, C., Marro, S., Kreslavsky, T., Marcora, E., & Goate, A. M. (2024) · Nature Communications · doi:10.1038/s41467-024-46315-7 · Cited by 52
Metadata
- Authors
- Jones, R. E., Andrews, R., Holmans, P., Hill, M., & Taylor, P. R.
- Affiliations
- UK Dementia Research Institute (GB)
- Cardiff University (GB)
- Corresponding author
- Taylor, Philip R.
- Venue
- Scientific Reports
- Published
- 2021-07-22
- Volume
- 11
- Issue
- 1
- Pages
- 14935-14935
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC8298495
- OpenAlex
- W3133041819
- Cited by
- 39
- References
- 62
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 4 · 2023: 12 · 2022: 6 · 2021: 1
- FWCI
- 2.99
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Medical Research Council UK
- Wellcome Trust (107964/Z/15/Z)
- UK MRC Dementia Research Institute
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- PU.1, Alzheimer's disease, microglia, gene dosage, microglial transcriptome, interferon response, innate immune response, DNA replication, genetic risk variants, microglial phenotype
- MeSH terms
- Proto-Oncogene Protein Spi-1, Alzheimer Disease, Animals, Humans, Interferons, Proto-Oncogene Proteins, Signal Transduction, Trans-Activators, Sequence Analysis, RNA, Microglia, Gene Dosage, Polymorphism, Single Nucleotide, Gene Expression Profiling, Mice, Gene Regulatory Networks, Primary Cell Culture
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Modest changes in Spi1 dosage reveal the potential for altered microglial function as seen in Alzheimer’s disease. https://app.cochat.ai/papers/10.1038/s41598-021-94324-z
- The paper
- Jones, R. E., Andrews, R., Holmans, P., Hill, M., & Taylor, P. R. (2021). Modest changes in Spi1 dosage reveal the potential for altered microglial function as seen in Alzheimer’s disease. Scientific Reports. https://doi.org/10.1038/s41598-021-94324-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.